Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 53

1.

Role of farletuzumab in epithelial ovarian carcinoma.

Jelovac D, Armstrong DK.

Curr Pharm Des. 2012;18(25):3812-5.

PMID:
22591419
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Farletuzumab in epithelial ovarian carcinoma.

Spannuth WA, Sood AK, Coleman RL.

Expert Opin Biol Ther. 2010 Mar;10(3):431-7. doi: 10.1517/14712591003592069. Review.

PMID:
20092424
[PubMed - indexed for MEDLINE]
3.

Clinical trials and future potential of targeted therapy for ovarian cancer.

Itamochi H, Kigawa J.

Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28. Review.

PMID:
22926640
[PubMed - indexed for MEDLINE]
4.

A systematic overview of chemotherapy effects in ovarian cancer.

Högberg T, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):340-60. Review.

PMID:
11441940
[PubMed - indexed for MEDLINE]
5.

Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer.

Walters CL, Arend RC, Armstrong DK, Naumann RW, Alvarez RD.

Gynecol Oncol. 2013 Nov;131(2):493-8. doi: 10.1016/j.ygyno.2013.07.080. Epub 2013 Jul 14. Review.

PMID:
23863359
[PubMed - indexed for MEDLINE]
6.

Review of dose-intense platinum and/or paclitaxel containing chemotherapy in advanced and recurrent epithelial ovarian cancer.

Boere IA, van der Burg ME.

Curr Pharm Des. 2012;18(25):3741-53. Review.

PMID:
22591417
[PubMed - indexed for MEDLINE]
7.

Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer.

Teoh D, Secord AA.

Int J Gynecol Cancer. 2012 Mar;22(3):348-59. doi: 10.1097/IGC.0b013e31823c6efd. Review.

PMID:
22266932
[PubMed - indexed for MEDLINE]
8.

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA.

J Reprod Med. 2005 Jun;50(6):426-38. Review.

PMID:
16050567
[PubMed - indexed for MEDLINE]
9.

Medical therapy of advanced malignant epithelial tumours of the ovary.

Colombo N, Parma G, Bocciolone L, Franchi D, Sideri M, Maggioni A.

Forum (Genova). 2000 Oct-Dec;10(4):323-32. Review.

PMID:
11535983
[PubMed - indexed for MEDLINE]
10.

Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer.

Monk BJ, Dalton H, Farley JH, Chase DM, Benjamin I.

Crit Rev Oncol Hematol. 2013 May;86(2):161-75. doi: 10.1016/j.critrevonc.2012.09.012. Epub 2012 Nov 6. Review.

PMID:
23137764
[PubMed - indexed for MEDLINE]
11.

Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.

Thigpen T, Vance R, Puneky L, Khansur T.

Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97-107. Review.

PMID:
7835816
[PubMed - indexed for MEDLINE]
12.

Gynecological malignancies.

Schaebler DL, Schilder RJ, Young RC.

Cancer Chemother Biol Response Modif. 1996;16:564-91. Review.

PMID:
8639401
[PubMed - indexed for MEDLINE]
13.

Management of platinum-sensitive recurrent ovarian cancer.

Pfisterer J, Ledermann JA.

Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6. Review.

PMID:
16716798
[PubMed - indexed for MEDLINE]
14.

Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review.

García-Sáenz JA, Custodio A, Casado A, Vidart JA, Coronado PJ, Martín M, López-Tarruella S, Puente J, Fernández C, Díaz-Rubio E.

Clin Transl Oncol. 2011 Feb;13(2):121-32. doi: 10.1007/s12094-011-0629-6. Review.

PMID:
21324801
[PubMed - indexed for MEDLINE]
15.

Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.

ten Bokkel Huinink W, Carmichael J, Armstrong D, Gordon A, Malfetano J.

Semin Oncol. 1997 Feb;24(1 Suppl 5):S5-19-S5-25. Review.

PMID:
9122738
[PubMed - indexed for MEDLINE]
16.

The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.

Gui T, Shen K.

Cancer Epidemiol. 2012 Oct;36(5):490-6. doi: 10.1016/j.canep.2012.06.005. Epub 2012 Jul 20. Review.

PMID:
22818908
[PubMed - indexed for MEDLINE]
17.

Angiogenesis inhibitors in the treatment of epithelial ovarian cancer.

Han ES, Wakabayashi M, Leong L.

Curr Treat Options Oncol. 2013 Mar;14(1):22-33. doi: 10.1007/s11864-012-0220-6. Review.

PMID:
23288484
[PubMed - indexed for MEDLINE]
18.

[Epithelial ovarian cancer].

Hilpert F, Krause G, Venhoff L, Kühnle E, Schem C, Maass N.

Ther Umsch. 2007 Jul;64(7):375-80. Review. German.

PMID:
17948754
[PubMed - indexed for MEDLINE]
19.

Systemic therapy for ovarian cancer: current status and new treatments.

Ozols RF.

Semin Oncol. 2006 Apr;33(2 Suppl 6):S3-11. Review.

PMID:
16716797
[PubMed - indexed for MEDLINE]
20.

Future directions in the chemotherapy of ovarian cancer.

Ozols RF.

Semin Oncol. 1997 Oct;24(5 Suppl 15):S15-86-S15-90. Review.

PMID:
9346230
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk